http://ift.tt/1x3KoM3
What makes this latest failure particularly noteworthy is that it added to the growing skepticism in the industry about the future of cancer vaccines in general. Despite an intensive research effort, cancer vaccines have repeatedly flopped in clinical testing, or at best, have only shown marginal benefits, when compared to other available treatments -- such as Dendreon's Provenge for prostate cancer, and Amgen's (NASDAQ: AMGN ) T-Vec indicated for metastatic melanoma.
Going forward, I expect big pharma to continue to move away from cancer vaccines to focus on other types of immune-based therapies like checkpoint inhibitors. Unless something drastically changes, cancer vaccines no longer appear to be strong clinical candidates as monotherapies, and might only serve a minor role as "immune enhancers," when used in conjunction with other types of treatments.
Roche invest in winners. AMgen invests in duds! T-Vec, trebanib, and rilotumomab both fail.
What makes this latest failure particularly noteworthy is that it added to the growing skepticism in the industry about the future of cancer vaccines in general. Despite an intensive research effort, cancer vaccines have repeatedly flopped in clinical testing, or at best, have only shown marginal benefits, when compared to other available treatments -- such as Dendreon's Provenge for prostate cancer, and Amgen's (NASDAQ: AMGN ) T-Vec indicated for metastatic melanoma.
Going forward, I expect big pharma to continue to move away from cancer vaccines to focus on other types of immune-based therapies like checkpoint inhibitors. Unless something drastically changes, cancer vaccines no longer appear to be strong clinical candidates as monotherapies, and might only serve a minor role as "immune enhancers," when used in conjunction with other types of treatments.
Roche invest in winners. AMgen invests in duds! T-Vec, trebanib, and rilotumomab both fail.
T-vec you suck!
Aucun commentaire:
Enregistrer un commentaire